"Fred Hassan" is a managing director at Warburg Pincus, which he joined in 2011. He was the Chair (official)/Chairman of the Board and Chief Executive Officer of pharmaceutical company Schering-Plough from 2003 until November 3, 2009, when the company completed its merger with Merck & Co.

Hassan was the Chairman of the Board of Bausch & Lomb from March 2010 until its sale in 2013.

On October 29, 2009 Time Warner announced that Hassan would join their Board of Directors.

More Fred Hassan on Wikipedia.

We have delivered on our promise of achieving a turnaround in 1998 and double-digit earnings growth for the full year.

204

We continue to deliver on the promise we made when we began our turnaround in 1997 of achieving annual double digit earnings growth, ... Our results this quarter were again driven by strong growth in the U.S., where prescription sales increased 28 percent.

175

'Pharmacia' captures the focus of the new organization as an exceptionally fast-growing core pharmaceuticals business in the top tier of the industry.

160

Looking ahead, we continue on track to build Schering- Plough into a company with the strength and breadth to deliver long-term high performance. We are moving from survive mode into thrive mode.

154

We're realistic and know we may not be able to acquire these drugs in the next six to 12 months.

130

Our cholesterol franchise continues to be a critical growth driver.

111

2005 was a pivotal year for Schering-Plough. We began our Turnaround phase. We achieved our goal of growing revenues and earnings.

107

We halted a downward spiral.

95

We are building a special capability at Schering-Plough to respond to these and other challenges with innovation, speed and flexibility. We aspire to continue being the company delivering the most positive change of any in our peer group, as we work to deliver our Turnaround and advance our six- to eight-year Action Agenda for transformational change.

94